Our Pipeline

We’re focused on the innovative application of science and medicine

With patients at the center of everything we do, Sunovion has charted new paths to life-transforming treatments that reflect our ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurologic and respiratory disorders.

Candidate Indication/Target Phase
SUN-101/eFlow® Chronic obstructive pulmonary disease (COPD) Registration
Latuda Bipolar depression, children and adolescents Registration
Aptiom Partial-onset seizures, pediatric (monotherapy/adjunctive therapy) Registration
Dasotraline Attention deficit hyperactivity disorder (ADHD), adult Phase 3
Dasotraline Attention deficit hyperactivity disorder (ADHD), pediatric Phase 3
Dasotraline Binge eating disorder, adult Phase 3
APL-130277 OFF episodes associated with Parkinson’s disease Phase 3
SB-623 Chronic stroke Phase 2
SEP-363856 Schizophrenia Phase 2
SEP-363856 Parkinson’s disease psychosis Phase 2
DSP-2230 Neuropathic pain Phase 1
WT-2725 Hematologic and solid cancer Phase 1
DSP-1200 Treatment-resistant depression Phase 1
DSP-6745 Parkinson's disease psychosis Phase 1